Additionally, gain-of-function KIT mutations (e.g., D816V), along with alterations in CCAAT/enhancer-binding protein alpha (CEBPA) and colony-stimulating factor 3 receptor (CSF3R), increase JAK-STAT pathway sensitivity in AML (205). Here, CEBPA is linked to acute myeloid leukemia.